Serotonergic psychedelic: Difference between revisions

[[File:Psilocybin neural connections.jpg|315px|thumbnail|right|The diagram above demonstrates the neural connections associated with sobriety in comparison to being under the influence of psilocybin as demonstrated through the use of MRI scans. The width of the links is proportional to their weight and the size of the nodes is proportional to their strength. Note that the proportion of heavy links between communities is much higher (and very different) in the psilocybin group, suggesting greater integration<ref>Petri, G., Expert, P., Turkheimer, F., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014). Homological scaffolds of brain functional networks, 14–18. https://doi.org/10.1098/rsif.2014.0873</ref>]]

[[File:NeuroPsychDiagram.png|thumbnail|315px|right|Figure 1 - Activation of the prefrontal network and glutamate release by psychedelics. The figure shows a model in which hallucinogens, such as psilocin, lysergic acid diethylamide (LSD) and dimethyltryptamine (DMT), increase extracellular glutamate levels in the prefrontal cortex through stimulation of postsynaptic serotonin (5-hydroxytryptamine) 2A (5-HT 2A ) receptors that are located on large glutamatergic pyramidal cells in deep cortical layers (V and VI) projecting to layer V pyramidal neurons. This glutamate release leads to an activation of AMPA (α-amino-3-hydroxy-5-methyl-4- isoxazole propionic acid) and NMDA (N-methyl-d-aspartate) receptors on cortical pyramidal neurons. in addition, hallucinogens directly activate 5-HT2A receptors located on cortical pyramidal neurons. This activation is thought to ultimately lead to increased expression of brain-derived neurotrophic factor (BDNF).<ref>Vollenweider, F. X., & Kometer, M. (2010). The Neurobiology of Psychedelic Drugs: Implications for the Treatment of Mood Disorders. Nature Publishing Group, 11(9), 642–651. https://doi.org/10.1038/nrn2884</ref>]]

[[File:Lsd brain scan.jpg|thumbnail|315px|right|This image shows how, with eyes-closed, much more of the brain contributes to the visual experience under LSD (right image) than under placebo (left image). The magnitude of this effect correlates with participants’ reports of complex, dreamlike visions.<ref>Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., … Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1518377113</ref>]]

==Examples==

<div class='flex-panel'>

* [[1P-LSD]]

* [[AL-LAD]]

* [[LSZ]]

* [[PRO-LAD]]

* [[aMT]]

* [[DET]]

* [[MiPT]]

* [[PiPT]]

* [[4-PO-DMT]] (''Psilocybin'')

* [[4-HO-DMT]] (''Psilocin'')

* [[5-MeO-DALT]]

* [[5-MeO-MALT]]

* [[Mescaline]]

* [[Escaline]]

* [[Methallylescaline]]

* [[Proscaline]]

* [[2C-B]]

* [[2C-C]]

* [[2C-T-2]]

* [[2C-T-7]]

* [[DOB]]

* [[DOC]]

* [[DOM]]

* [[DOPR]]

* [[25B-NBOMe]]

* [[25C-NBOMe]]

* [[25I-NBOMe]]

* [[25N-NBOMe]]

* [[2C-B-FLY]]

* [[Bk-2C-B|ßk-2C-B]]  

* [[TMA-2]]

* [[TMA-6]]

* [[Ayahuasca]]

* [[Syrian Rue]]

* [[Iboga]]

* [[Psilocybe Mushroom]]

* [[Harmaline]]

* [[Harmine]]

* [[Tetrahydroharmine]]

* [[5-MeO-DiBF]]

* [[Efavirenz]]

* [[Mirtazapine]]

</div>